On Jun. 2, 2021, Lonza announced the expansion of its collaboration with Moderna. The expanded collaboration extended the manufacture of the drug substance for the COVID-19 Vaccine Moderna and provided for the installation of a new manufacturing line for drug substance production at Lonza’s Geleen site.

The new production line contributed to the supply of up to an additional 300 million doses per year, at a 50ug dose, once operating at full capacity.